Literature DB >> 19925033

Human epidermal growth factor receptor dimerization analysis in breast cancer diagnosis: potential for improving testing accuracy and treatment selection.

Melanie Spears1, John M S Bartlett.   

Abstract

Our understanding of the human epidermal growth factor receptor (HER) family of proteins has increased over the last few decades. It is clear from the vast assortment of research that has been and is currently being carried out that there is still a lot to be learned. HER dimerization is known to activate various downstream pathways that have an effect on treatment and therapy for breast cancer. HER dimerization acts as a mechanism not only for amplifying the signal pathway but also for signal diversification. There is clear evidence that molecular subtypes of cancer respond differently to different therapeutic options, which challenges the 'one size fits all' approach to chemotherapy in cancer. Here, we review the methods by which HER dimerization can be explored and the potential that this has in the treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925033     DOI: 10.1007/BF03256341

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  58 in total

1.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

Authors:  Rita Nahta; Linda X H Yuan; Bing Zhang; Ryuji Kobayashi; Francisco J Esteva
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

2.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.

Authors:  M A Olayioye; I Beuvink; K Horsch; J M Daly; N E Hynes
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

4.  EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.

Authors:  Rohit Bhargava; William L Gerald; Allan R Li; Qiulu Pan; Priti Lal; Marc Ladanyi; Beiyun Chen
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

5.  Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation.

Authors:  Ami Citri; Judith Gan; Yaron Mosesson; Gyorgi Vereb; Janos Szollosi; Yosef Yarden
Journal:  EMBO Rep       Date:  2004-12       Impact factor: 8.807

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors:  Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

8.  Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

Authors:  R R Beerli; D Graus-Porta; K Woods-Cook; X Chen; Y Yarden; N E Hynes
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

9.  ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases.

Authors:  K S Spencer; D Graus-Porta; J Leng; N E Hynes; R L Klemke
Journal:  J Cell Biol       Date:  2000-01-24       Impact factor: 10.539

10.  Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

Authors:  C Wallasch; F U Weiss; G Niederfellner; B Jallal; W Issing; A Ullrich
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

View more
  1 in total

1.  Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.

Authors:  Lisa DeFazio-Eli; Kristi Strommen; Trang Dao-Pick; Gordon Parry; Laurie Goodman; John Winslow
Journal:  Breast Cancer Res       Date:  2011-04-15       Impact factor: 6.466

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.